ライフサイエンスコーパス: transforming growth factor beta2

1 ial-to-mesenchymal transition in response to transforming growth factor-beta2.

2 Furthermore, transforming growth factor beta2 alters the morphology a

3 raviolet induction of Smad7 and reduction of transforming growth factor beta2 and transforming growth

4 rial effects of HOXA9-induced, tumor-derived transforming growth factor-beta2 and chemokine ligand 2

5 lls resulted in the sequential production of transforming growth factor-beta2 and interleukin-10, whi

6 injury with an increase in molecules such as transforming growth factor-beta2 and matrix metalloprote

7 n the delayed wound healing, suggesting that transforming growth factor-beta2 and/or transforming gro

8 tion of the genes encoding CD68, CD53, CD24, transforming growth factor beta2, and signal transducers

9 ulation of transforming growth factor-beta1, transforming growth factor-beta2, and collagens I and II

10 nes and cytokines, such as CXCL10, CCL2, and transforming growth factor-beta2, and of chondroitin sul

11 e human monoclonal antibody that neutralizes transforming growth factor-beta2 (CAT-152; lerdelimumab)

12 g growth factor beta receptor V in mediating transforming growth factor beta2 enhancement of amyloid

13 rleukin-6 gene, c-myc, cdc-2, c-neu, and the transforming growth factor beta2 gene.

14 lin-like growth factor binding protein 4 and transforming growth factor beta2), glyceraldehyde-6-phos

15 ssion of macrophage inhibitory protein-2 and transforming growth factor-beta2 in the kidney.

16 Transforming growth factor-beta2-induced EMT was further

17 w and lysosomal hydrolase analysis show that transforming growth factor beta2 makes lysosomal membran

18 Transforming growth factor beta2 may alter this pathway

19 factor beta2-treated cells demonstrate that transforming growth factor beta2 modestly increases the

20 ctor beta1 and beta3 mRNA were increased and transforming growth factor beta2 mRNA was reduced throug

21 In contrast, expression of transforming growth factor beta2 mRNA, the predominant f

22 In contrast, the percentage of transforming growth factor beta2-positive cells decrease

23 Confocal imaging reveals that transforming growth factor beta2 rapidly targets amyloid

24 to platelet-derived growth factor (PDGF) and transforming growth factor beta2 (TGF-beta).

25 Transforming growth factor beta2 (TGF-beta2) induced alp

26 for forkhead transcription factor binding in transforming growth factor beta2 (TGF-beta2) promoter.

27 s were observed when cells were treated with transforming growth factor beta2 (TGF-beta2), another fa

28 of endothelial cells strongly downregulates transforming growth factor beta2 (TGF-beta2).

29 Transcription of the transforming growth factor-beta2 (TGF-beta2) gene is dep

30 Transforming growth factor-beta2 (TGF-beta2) has recentl

31 Increased levels of active transforming growth factor-beta2 (TGF-beta2) in the aque

32 We have shown previously that transforming growth factor-beta2 (TGF-beta2) is a geneti

33 Transforming growth factor-beta2 (TGF-beta2) is an impor

34 ansfected endothelial cells with the ligands transforming growth factor-beta2 (TGF-beta2) or bone mor

35 pt coincided with an increased expression of transforming growth factor-beta2 (TGF-beta2) transcript.

36 Transforming growth factor-beta2 (TGF-beta2) was predomi

37 ncreases messenger RNA and protein levels of transforming growth factor-beta2 (TGF-beta2), a cytokine

38 In the present study, we identified transforming growth factor-beta2 (TGF-beta2), an isoform

39 to epithelial transition (MET) and inhibits transforming growth factor-beta2(TGF-beta2)-induced EMT

40 e known EMT inducers ZEB1, ZEB2, Snail1, and transforming growth factor beta2 (TGFB2).

41 were investigated further as pure proteins: transforming growth factor beta2 (TGFbeta2) and fibrobla

42 This inhibition is associated with decreased transforming growth factor beta2 (TGFbeta2) and phospho-

43 e current study identifies the gene encoding transforming growth factor beta2 (TGFbeta2) as a HoxA10

44 Instead, transforming growth factor beta2 (Tgfbeta2) might contro

45 12.5 embryos demonstrated elevated levels of transforming growth factor beta2 (TGFbeta2) protein in m

46 ith HDAC3 and Akt1 and selectively activates transforming growth factor beta2 (TGFbeta2) secretion an

47 Notably, transforming growth factor beta2 (TGFbeta2), a key effec

48 rk cells insulted by dexamethasone (DEX) and transforming growth factor beta2 (TGFbeta2), factors ass

49 We find that transforming growth factor beta2 (TGFbeta2), predominant

50 Transforming growth factor-beta2 (TGFbeta2) has been imp

51 The growth and differentiation factor transforming growth factor-beta2 (TGFbeta2) is thought t

52 RT-PCR and Western blot analysis of transforming growth factor beta2-treated cells demonstra

53 Transforming growth factor-beta2-treated Ag-pulsed APC m

54 ular adhesion molecule-1, interleukin-8, and transforming growth factor-beta2, was significantly grea

55 terleukins-10 and -12, interferon-gamma, and transforming growth factor-beta2 were detected in aqueou

56 Expression levels of both interleukin-10 and transforming growth factor-beta2 were elevated whereas r

57 investigation of a ligand for this receptor, transforming growth factor beta2, which is also implicat